

WDN:SLR 09/05/03 217636.doc
PATENT

Attorney Reference Number 6395-62068
Application Number 10/048,146

Remarks

Applicants elect Group II (claims 1, 2, 3 and 5) directed to a composition comprising the TS-18 polypeptide of *T. solium* or antigenic fragments thereof, with traverse.

Claims 1-16 were pending. Due to the restriction requirement, claims 6-16 were cancelled without prejudice to prosecution in another application. Claims 2-5 were amended to clarify the claims. Support can be found in claim 1. Claims 17-28 are added. Therefore, claims 1-5 and 17-28 are now pending. Support for the new claims can be found throughout the specification, for example:

Claim 17: page 23, lines 10-20

Claims 18-19: page 18, line 15 - page 19 line 15

Claims 20-22: page 23, lines 21-28

Claim 23: page 14, lines 1-6 and page 14, line 30- page 15, line 4

Claim 24-25: page 8, lines 17-23

Claims 26-28: claim 2

Groups I - IV should be examined in the same application. As the Restriction Requirement correctly states on page 3, the polypeptide or antigenic fragment thereof claimed in claim 1 is the special technical feature unifying inventions I-IV. However, the Restriction Requirement concludes that Ryan *et al.*, *Mol. Biochem. Parasitol.* 99:257-61, April 1999 (this should be cited as Greene *et al.* as Ryan is the author's first name) teaches an antigenic fragment and therefore the special technical feature does not define over the prior art. Applicants respectfully disagree and request reconsideration.

Greene *et al.* is not available as prior art under § 102(b) with respect to the present application because it was published less than one year prior to the Applicants' priority date of August 5, 1999. Nor is Greene *et al.* available as prior art under § 102(a) because it is not the work of another since Greene *et al.* describes the work of 3 of the 4 co-inventors.

WDN:SLR 09/05/03 217636.doc
PATENT

Attorney Reference Number 6395-62068
Application Number 10/048,146

As stated in the enclosed Rule 1.132 Declarations, Greene *et al.* discloses subject matter derived from three of the four co-inventors (Greene, Wilkins, and Tsang) of the present application. The other co-inventor Hancock was not listed as an author because she was not involved in the protein purification aspect of the project. However, Hancock is a co-inventor of the presently claimed subject matter because she was involved in the recombinant cloning of the full-length sequences. Greene *et al.* is therefore not prior art with respect to the present application and cannot be used to assert a lack of unity of invention. The restriction requirement does not establish a prima facie case of lack of unity because the reference relied upon to make that argument is not available as prior art.


Group IV should not be separated from Groups I-III because SEQ ID NO: 7 is an antigenic subsequence of the TS-14, TS-18, and TSRS-1 polypeptides of *T. solium*. SEQ ID NO: 7 is shown as amino acids 78-83 of SEQ ID NO: 2 (TS-14), amino acids 40-45 of SEQ ID NO: 4 (TS-18), and amino acids 39-44 of SEQ ID NO: 6 (TSRS-1).

Therefore, Applicants respectfully request that Groups I-IV be re-joined and examined in a single application.

If there are any questions regarding the present response, the examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

OFFICIAL
RECEIVED
CENTRAL FAX CENTER

SEP 08 2003

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446